Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Show Description +

Dr. Barakat discusses the baseline characteristics and outcomes of patients treated with 8 mg aflibercept (Eylea HD, Regeneron) at shortened, maintained, or extended dosing intervals.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

aflibercept

•

Eylea

•

Regeneron Pharmaceuticals

•

dosing

•

EyleaHD

•

extended intervals

Up Next

Name: Dosing Considerations with 8 mg Aflibercept
Uploaded: 2025-05-12T20:13:06+00:00
Description: Dr. Barakat discusses the baseline characteristics and outcomes of patients treated with 8 mg aflibercept (Eylea HD, Regeneron) at shortened, maintained, or extended dosing intervals.

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Back to All Videos

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Dr. Barakat discusses the baseline characteristics and outcomes of patients treated with 8 mg aflibercept (Eylea HD, Regeneron) at shortened, maintained, or extended dosing intervals.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

aflibercept

•

Eylea

•

Regeneron Pharmaceuticals

•

dosing

•

EyleaHD

•

extended intervals

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

Dosing Considerations with 8 mg Aflibercept

Up Next

Dosing Considerations with 8 mg Aflibercept

More From ARVO: 2025 Coverage